Aster DM Quality Care

“I'm also not saying it's going to play out this quarter, but you will start to see significant results on our synergies this financial year onwards. That'll get annualized as we go forward into the next year.”

“Of course, there is efforts that we are doing to make sure that we are able to kind of make it a bigger proportion of our overall revenue. I think trying to get it to double digit is sort of a goal that we will have over the next couple of years”

“I think we are talking about anywhere double-digit growth. Even the lower to mid-teen growth. I think that is something which is sustainable.”

“Capital deployment will focus on deepening presence across our core Southern, Central, and Eastern regions.”

“I think we have said H2 FY 2027, and most probably somewhere in the month of January, we should be able to operationalize the Trivandrum hospital.”

“Currently, we are more or less doing the interior works there, and we'll start ordering the medical equipment in next one or two months. If that goes well, I think we should be able to operationalize sometime in the April 2027.”

“Going well, I think at least the phase I, which is the first A block, we should be able to operationalize in the second half of FY28.”

“By the way, the good news is that we are inaugurating our cancer center in Raipur right away. That was one big project for us. That's coming up in the middle of this month.”

“Growth across our unit mix remained robust with Mature Units contributing 73% to the total revenue recorded 19% YoY revenue growth”

“The strong operating leverage led to the EBITDA growth of 29% in this segment and sustained EBITDA margins at 30% expanding by 230 bps YoY.”

“Focus Units (15% of the revenue) delivered 16% YoY revenue growth, benefiting from expanding specialty programs, increasing occupancy, and rapid margin expansion further leading to EBITDA growth of 20% with EBITDA margins expansion of 60 bps.”

“Emerging Segment which is the newer hospitals registered the highest growth trajectory at 63% YoY revenue growth, propelled by fast-paced patient volume ramp-ups at newly commissioned facilities.”

“In our Emerging Units, EBITDA surged by 240% YoY, with margins more than doubling to 12.4% with 640 bps YoY expansion.”

“This was supported by 62% YoY growth in Medical Value Travel (MVT) revenue on account of addition of new geographies.”

“We treated over 2 million patients in Q1, up 13% YoY, with blended occupancy expanding 510 bps YoY to 64%.”

“Revenue growth was driven by higher patient volumes supported by higher realizations driven by an increasingly complex case mix.”

“IP is driven by more than 16% volumes. OP has been 19% volumes.”

“This strong performance was driven by a 656 bps jump in occupancy to 65.4%, deeper clinical mix, robust growth in robotic, transplants and joint replacement along with better payor mix which boosted the ARPP IP, reaching ~INR 144k in Q1FY27.”

“EBITDA growth outpaced revenue growth, unlocking operating leverage through material cost savings and stronger fixed cost absorption.”

“For merged entity, synergies haven't played out. As I told you, we've not started working on the merged entity synergies previously.”

“It's a 10-point synergy wheel that we created, I had mentioned this about a year back as well, that those are the things that one should work on. First and foremost, of course, it is led by the benefit on consumption.”

“At the combined level there is a net debt of INR 1162 Crore as on 30 June 2026. Aster is net cash with INR 511 crore and Quality Care has a debt of INR 1,673 crore.”

“Considering that the merger became effective on July 1, 2026, the numbers pertaining to the combined entity are on proforma basis.”

“I think the first and the foremost thing is that we brought these two large companies together so that we could benefit from scale. That is what draws me to the post-merger integration and value unlocking from the synergies.”

“We know exactly what kind of initiatives will get us there, what are the revenue synergies, what are the cost synergies.”

“I think this is a really important year ahead for us, and I cannot underplay how important it is for us to just get these two platforms to run cohesively and synergistically”

“Another part of Kerala and Karnataka is together. We've got Andhra, Telangana, Central, and a part of East together.”

“There's somebody who's going to lead clinical specialties. Someone's going to be focusing on oncology, someone's going to be focusing on cardiology, because that's another vertical that we are developing.”

“See, the India leadership, we are still in the process of putting all of the final touches to it.”

“It's more of drawing inspiration from a multinational company. It's a matrixed setup to ensure that we are getting the best of thought process and operational control.”

“The exceptional expense of INR 114 Cr pertains entirely to costs incurred”

“towards the merger and related activities. These are one-time, transaction-related costs and are not indicative of the underlying operating cost base.”

“See, we've always seen whether it's in Kerala or Karnataka, whenever there is a neighborhood competition coming in, you will have some softness in the growth for one or two quarter, slowly it'll come back.”

“Karnataka, yes, FY26, I think the first two or three quarters, we had a little bit of attrition in some of the doctors, and we went into even a single digit growth.”

“operations increased 20% year-on-year to INR 2,597 crores. EBITDA grew 30% YoY to INR 576 crores. The EBITDA Margin expanded by 170 bps YoY to 22.2%.”

“with revenue increasing 22% year-on-year to Rs. 1,311 Cr, compared to Rs. 1,078 Cr in Q1 FY26. Operating EBITDA increased 29% to Rs. 277 Cr, while the operating EBITDA margin expanded by 117 basis points to 21.1%.”

“Normalised PAT, excluding exceptional costs, increased 39% year-on-year to approximately Rs. 125 Cr, compared with Rs. 90 Cr in the corresponding quarter last year.”

“Return on Capital Employed improved by approximately 190 basis points to 22.6%, compared with 20.7% in the corresponding period last year.”

“There is a huge leverage that we will have in terms of our clinical programs when it comes to managing complexity.”